Compound developed by CDRD and BCCA licensed

A new oncology compound developed by the Centre for Drug Research and Development and the BC Cancer Agency has been licensed to Baltimore, MD-based Champions Oncology Inc. Irinophore is a lipid-based nanoparticle developed by using a proprietary method developed by BCCA that has demonstrated the ability to ameliorate a critical side effect of Camptosan, the standard-of-care treatment for colorectal cancer. Irinophore is the first compound to be licensed as a result of collaboration between CDRD and BCCA. The drug is completing preclinical development and is slated to enter a Phase I clinical study in Q4/11 for the treatment of patients with advanced solid tumors….